Searchable abstracts of presentations at key conferences in endocrinology

ea0011p611 | Neuroendocrinology and behaviour | ECE2006

Octreotide shrinks the cellular rather than the vascular compartment in acromegalic tumours in vivo

Manuchehri AM , Lowry M , Rowland Hill C , Turnbull LW , Atkin SL

Rationale: Octreotide is known to shrink acromegalic tumours in vivo. However, the mechanism for this is unclear. To investigate the mechanism of shrinkage we used dynamic contrast enhanced MR imaging (DCE-MRI) to visualise the vascular components within the somatotroph adenomas.Subjects & Methods: Six patients with confirmed acromegaly comprising 4 microadenomas (all male) and 2 macroadenomas (1 male, 1 female) were recruited. All patients we...

ea0009oc7 | Oral Communication 1: Diabetes and metabolism | BES2005

Calcitonin Gene Related Peptide (CGRP)II mRNA in human subcutaneous adipose tissue is altered by menopausal status

Gupta P , Harte A , Hill M , Barnett A , Sturdee D , Kumar S , McTernan P

CGRP, a potent vasodilator, is elevated in the intense periods during menopausal hot flushes and presently represents a candidate mediator of vasomotor symptoms. However due to the short half-life of CGRP, the local paracrine effects may be more important than systemic effects. These local paracrine effects may be mediated in conjunction with adipose tissue, due to close physical proximity with the vasculature; as well as altered oestrogen metabolism following menopause. There...

ea0009p21 | Diabetes and metabolism | BES2005

Fatty liver disease is associated with both endotoxaemia and sub-clinical inflammation which is further aggravated by diabetes

Silva N , Harte A , Hill M , Kumar S , Day C , McTernan P

Obesity-mediated diabetes is associated with insulin resistance/hyperinsulinaemia and chronic sub-clinical inflammation. Recent studies have highlighted fatty liver(steatosis) as a risk factor for diabetes. Fatty liver disease (FLD) progresses through fatty liver, necro-inflammation (non-alcoholic steatohepatitis, NASH) and fatwith fibrosis. In addition, hepatic steatosis per se can lead to hepatic insulin resistance/hyperin...

ea0007oc31 | Diabetes and metabolism | BES2004

Inducing pancreatic beta cell regeneration; interactions of transcription factors and peptide growth factors

Leadbeater W , Thyssen S , Strutt B , Chamson A , Arany E , Pin C , Logan A , Hill D

Pancreatic islet cell transplantation is proven to restore functional beta cell mass to achieve normoglycemia in diabetics, but is limited by low availability of human cadaveric donor tissue. A strategy to build capacity is to use stem cells (SCs), and induce their expansion and differentiation into functional islets in vitro. Islet cell neogenesis has been linked to transient and sequential expression of specific transcription factors (TFs) and the actions of endogenou...

ea0007p143 | Growth and development | BES2004

Pregnancy-induced plasticity in rat pituitary: a morphological and endocrine study of somatotroph and lactotroph function

El-Kasti M , Christian H , Huerta I , Hill N , Matthews D , Wells T

Pregnancy is associated with increased circulating growth hormone (GH), which is thought to originate from the placenta in humans, but from the pituitary in rats. In this study we investigated the changes in somatotroph and lactotroph populations, and quantified spontaneous and secretagogue-induced GH and prolactin (PRL) secretion during pregnancy in rats.Using electron microscopy and immunogold labelling, somatotroph and lactotroph populations were quan...

ea0005p143 | Endocrine Tumours and Neoplasia | BES2003

Transcriptional regulation by PEA3 in human breast cancer

Myers E , Buggy Y , Hill A , Duffy M , O'Higgins N , Young L

Her-2/neu over-expression is associated with elevated tumorigenicity and enhanced metastatic potential. Recently a DNA motif containing the consensus binding site of PEA3, a member of the ets transcription factor family has been identified on the Her-2/neu promoter. Activation of the PEA3 response element has been proposed to be involved in the transcriptional squelching of Her-2/neu.Methods: Using RT-PCR we have determined PEA3 mRNA expression in human breast tissue and l...

ea0005p194 | Reproduction | BES2003

Insulin sensitivity in polycystic ovary syndrome-influence of peroral versus transdermal estrogen treatment

Vrbikova J , Stanicka S , Dvorakova K , Hill M , Vondra K , Starka L

Aim: To compare influence of transdermal versus peroral estrogen treatment on insulin sensitivity, lipid and hormonal levels in women affected with polycystic ovary syndrome (PCOS).Patients and Methods: 17 women with PCOS, age 24.8 (4.2) years, BMI 24.15 (3.68) were randomly assigned either for peroral (8) or transdermal (9 patients) estrogens in conjunction with cyproteronacetate. In the early follicular phase of menstrual cycle before and then after 3 month of treatment ...

ea0003p134 | Endocrine Tumours and Neoplasia | BES2002

A role for co-regulators in estrogen receptor function

Fleming F , Hill A , Duffy M , McDermott E , O'Higgins N , Young L

The estrogen receptor is encoded by two genes (ER-alpha and ER-beta). Both function as transcription factors to modulate expression of target genes. ER-alpha has been shown to interact with co-regulators to enhance or inhibit transcription in vitro. We hypothesised that the existence of these co-regulators contribute to the differing clinical response of patients to treatment with the anti-estrogen four hydroxytamoxifen (4-HOT). The aim of this project was to localise ER-alpha...

ea0068p22 | Abstracts | UKINETS2019

Sheffield experience of administering Lutathera as a day case treatment

Maynard Alec , Hill Steven , Hallam Anna , Sabbagh Ahmad , Brown Colleen , Munir Alia , Newell-Price John , Wadsley Jonathan

Introduction: Lutetium-177 Oxodotreotide (Lutathera) is a targeted molecular radiotherapy treatment for advanced, inoperable, progressive neuro-endocrine tumours. We present our experience of Lutathera therapy with particular focus on our experience implementing treatment as a day-case procedure, and assessment of adherence to treatment quality standards surrounding the administration.Aims: To assess safety of Lutathera as a day-case treatment.<p cla...

ea0068p36 | Abstracts | UKINETS2019

Two case reports of preserved endocrine and exocrine function in VHL patients with extensive pancreatic cysts

El Sayed Ahmed , Boharoon Hessa , Alsafi Ali , Preitner Nadia , Kosicka-Slawinska Monika , Brady Angela , Hill Peter , Tan Tricia

Von Hippel-Lindau (VHL) disease is an inherited tumour syndrome, caused by a mutation in the VHL tumour suppressor gene encoding the VHL protein. Patients are prone to cysts and neuroendocrine tumours in the pancreas and other benign and malignant neoplasms. Pancreatic cysts occur in approximately 70% of VHL patients. We describe two cases of VHL disease with extensive multi-cystic changes affecting the whole pancreas, both patients had deletions of exon 2–3 of the VHL ge...